KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Non-Current Debt (2016 - 2020)

Historic Non-Current Debt for Nektar Therapeutics (NKTR) over the last 9 years, with Q1 2020 value amounting to $254.8 million.

  • Nektar Therapeutics' Non-Current Debt rose 299.69% to $254.8 million in Q1 2020 from the same period last year, while for Mar 2020 it was $254.8 million, marking a year-over-year increase of 299.69%. This contributed to the annual value of $250.0 million for FY2019, which is 123.51% up from last year.
  • Per Nektar Therapeutics' latest filing, its Non-Current Debt stood at $254.8 million for Q1 2020, which was up 299.69% from $250.0 million recorded in Q4 2019.
  • In the past 5 years, Nektar Therapeutics' Non-Current Debt registered a high of $254.8 million during Q1 2020, and its lowest value of $242.1 million during Q1 2016.
  • Moreover, its 5-year median value for Non-Current Debt was $245.6 million (2018), whereas its average is $246.0 million.
  • Its Non-Current Debt has fluctuated over the past 5 years, first surged by 9405.36% in 2016, then surged by 70.71% in 2019.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Non-Current Debt stood at $243.5 million in 2016, then rose by 0.72% to $245.2 million in 2017, then rose by 0.71% to $247.0 million in 2018, then rose by 1.24% to $250.0 million in 2019, then rose by 1.92% to $254.8 million in 2020.
  • Its last three reported values are $254.8 million in Q1 2020, $250.0 million for Q4 2019, and $248.3 million during Q3 2019.